Pharmaceutical combinations and pharmaceutical compositions for the treatment of cancer
CN117479958BActive Publication Date: 2026-06-05CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
- Filing Date
- 2023-05-30
- Publication Date
- 2026-06-05
AI Technical Summary
Technical Problem
Existing FGFR4 inhibitors suffer from insufficient selectivity and significant side effects when treating cancer, especially liver cancer, leading to off-target effects and toxicity.
Method used
The compound of formula (I) is used in combination with CDK inhibitors, lenvatinib or sorafenib to form a drug combination, which improves efficacy and reduces side effects through low-dose administration.
Benefits of technology
It significantly improved the treatment effect on cancer, especially liver cancer, while reducing drug side effects and improving the safety of medication.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN117479958B_ABST
Abstract
A pharmaceutical combination and pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and the use thereof in the manufacture of a medicament for the treatment of a malignant neoplastic disease. Wherein the other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as ribociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the foregoing.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Combination therapies for the treatment of hepatocellular carcinoma
CN109803684A
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN110022900A
Heterocyclic compound serving as FGFR4 inhibitor
WO2017202390A1
Heterocyclic compound as inhibitor of FGFR4
CN108948004A
Combination therapies for the treatment of hepatocellular carcinoma
CN111787922A